Ceritinib Displays Whole Body, Intracranial Efficacy in Crizotinib-treated Patients
Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.
Ceritinib treatment demonstrated clinically meaningful whole body and intracranial activity with an acceptable tolerability profile.
Brigatinib demonstrated antitumor activity in crizotinib-treated and crizotinib-naïve patients with non-small cell lung cancer (NSCLC).
The addition of gefitinib to first-line pemetrexed plus carboplatin prolongs progression-free survival compared with chemotherapy alone and gefitinib alone.
BI 1482694 demonstrated meaningful clinical activity in patients with EGFR TKI-resistant non-small cell lung cancer (NSCLC).
Tolerability-guided dose adjustment of the kinase inhibitor afatinib reduced treatment-related adverse events without negatively impacting efficacy.
Patients with clinically diagnosed early-stage lung cancer were found to have improved cancer-specific survival.
Different EGFR mutation subtypes are associated with different clinical and demographic characteristics.
Afatinib significantly prolonged progression-free survival (PFS) for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).